In line with these findings, we observed that patients with LFS harboring a P/LP TP53 variant with a co-occurring germline hit in another cancer gene (class 1–3) were associated with increased cancer incidence and decreased cancer survival compared with variant TP53 carriers lacking any class 1–3 variants. The gene discussed is TP53; the disease is cancer.